Compare LTC Properties Inc (LTC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Summit Therapeutics Inc — how do they compare? LTC Properties Inc trades at $42.53 (market cap $2.27B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 6× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.42% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Summit Therapeutics Inc for 16 Days on average.
| LTC | SMMT | |
|---|---|---|
Market Cap | $2.27B | $13.71B |
Volume | 574,171 | 6,173,057 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $26.38 |
52-Week Low | $33.98 | $12.43 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $3.01B | $13.04B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.46, up 1.55% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 61.72% gross margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, though cash flow trends show significant investing outflows. Analyst consensus targets $49.67 with 32% buy ratings amid balanced risk-reward outlook.
LTC presents a balanced opportunity with steady income from monthly dividends and demographic tailwinds in senior housing, offset by execution risks from rapid portfolio transformation and rising interest rate sensitivity. The stock trades at reasonable valuations (P/E 15.02) but faces headwinds from its SHOP transition strategy and macroeconomic pressures on REIT valuations.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
